Literature DB >> 33226447

Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.

Haofeng Lu1,2, Lin Zhou2, Hongping Zuo2, Wenjin Le2, Jianfei Hu2, Tiequan Zhang2, Mi Li2, Yufeng Yuan3.   

Abstract

BACKGROUND: The survival benefit of sorafenib, the most used drug for advanced hepatocellular carcinoma (HCC), is unsatisfactory due to the development of adaptive resistance. Exploring the mechanisms underlying sorafenib resistance is important to develop sensitizing strategy. Sphingomyelin synthase (SMS) plays a critical role in sphingolipid metabolism which is involved in oncogenesis and drug resistance.
METHODS: SMS1 and SMS2 levels in HCC cells in response to prolonged chemotherapy were analyzed using ELISA. mRNA and protein levels of SMS in HCC and adjacent normal tissues were analyzed by ELISA and real-time PCR. The roles of SMS and its downstream targets were investigated using cellular and biochemical assays and mass spectrometry.
RESULTS: SMS1, but not SMS2, was upregulated in HCC in response to sorafenib treatment, although HCC displayed similar RNA and protein level of SMS1 compared to adjacent normal liver tissues. Overexpression of SMS1 promoted HCC growth and migration, and alleviated sorafenib's toxicity. SMS1 inhibition via genetic and pharmacological approaches consistently resulted in inhibition of growth and migration, and apoptosis induction in sorafenib-resistance HCC cells. SMS1 inhibition also augmented the efficacy of sorafenib in sensitive HCC cells. SMS1 inhibition disrupted sphingolipid metabolism via accumulating ceramide and decreasing sphingomyelin, inducing mitochondrial dysfunction and oxidative stress, and decreasing Ras activity in resistant cells. Overexpression of constitutively active Ras reversed the inhibitory effects of SMS1 inhibition. Although SMS1 overexpression did not affect Ras expression and activity, Pearson correlation coefficient analysis of SMS1 and Ras expression demonstrated that there was positive correlation between SMS1 and RAS (NRAS, R = 0.55, p < 0.01; KRAS, R = 0.44, p < 0.01).
CONCLUSIONS: Our work is the first to suggest that SMS1 plays a more important role in sorafenib resistance than tumorigenesis, and provides preclinical evidence to overcome sorafenib resistance with SMS1 inhibition in HCC.

Entities:  

Keywords:  Hepatocellular carcinoma; Ras; SMS1; Sorafenib resistance; Sphingolipid

Year:  2020        PMID: 33226447     DOI: 10.1007/s00280-020-04199-6

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  1 in total

1.  Sphingomyelin synthase 1 regulates the epithelial‑to‑mesenchymal transition mediated by the TGF‑β/Smad pathway in MDA‑MB‑231 cells.

Authors:  Shuang Liu; Huan Hou; Panpan Zhang; Yifan Wu; Xuanhong He; Hua Li; Nianlong Yan
Journal:  Mol Med Rep       Date:  2018-12-04       Impact factor: 2.952

  1 in total
  3 in total

1.  Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism.

Authors:  Pei-Wei Shueng; Hui-Wen Chan; Wei-Chan Lin; Deng-Yu Kuo; Hui-Yen Chuang
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

2.  Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells.

Authors:  Alejandro Español; Yamila Sanchez; Agustina Salem; Jaqueline Obregon; Maria Elena Sales
Journal:  World J Clin Oncol       Date:  2022-06-24

3.  Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer.

Authors:  Lei Zhang; Risheng She; Jianlin Zhu; Jin Lu; Yuan Gao; Wenhua Song; Songwang Cai; Lu Wang
Journal:  BMC Cancer       Date:  2022-10-01       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.